Oaktree Acquisition Corp. III Life Sciences OACC FINANCIAL
Company Overview
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -14.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -14.40% |
Stock Price Performance
| 1 Year: | +3.15% |
| 6 Months: | +1.22% |
| 3 Months: | +1.41% |
| 1 Month: | +0.56% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.46 · Neutral
P/E of 38.57 is above the sector median of 12.89 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Financial Services).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OACC Oaktree Acquisition Corp. III Life Sciences FINANCIAL | 10.80 | 38.57 | $213.66M | 0.00% | -0.59% | -107.66% | - | - |
| 2 | JPM JPMorgan Chase & Co. SPXR3KFINANCIAL | 353.51 | 15.15 | $939.70B | 1.72% | - | 17.79% | 12.50% | 14.83% |
| 3 | BRK-B Berkshire Hathaway Inc. SPXFINANCIAL | 505.83 | 12.72 | $712.23B | 0.00% | - | 12.12% | 4.18% | 9.44% |
| 4 | V Visa Inc. SPXR3KFINANCIAL | 368.64 | 31.35 | $628.20B | 0.72% | 37.15% | 61.19% | 14.33% | 13.04% |
| 5 | MA Mastercard Incorporated SPXR3KFINANCIAL | 570.89 | 31.44 | $496.37B | 0.62% | 60.19% | - | 12.29% | 19.21% |
| 6 | BAC Bank of America Corporation SPXR3KFINANCIAL | 62.39 | 14.41 | $436.28B | 2.04% | - | 11.20% | 3.14% | 4.27% |
| 7 | BRK-A Berkshire Hathaway Inc. FINANCIAL | 757,791.00 | 12.71 | $370.14B | 0.00% | - | 12.12% | 7.60% | 10.02% |
| 8 | HSBC HSBC Holdings plc FINANCIAL | 106.26 | 15.18 | $363.70B | 3.65% | - | 13.10% | 9.75% | 12.72% |
| 9 | MS Morgan Stanley SPXR3KFINANCIAL | 216.24 | 17.48 | $339.62B | 2.26% | - | 17.97% | 3.76% | 9.66% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Income | -48.09K | -444.80K | -269.81K | -225.58K | -456.54K |
| Net Income | -48.09K | 1.66M | 1.87M | 1.97M | 1.39M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Income | -1.20M |
| Net Income | 7.29M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 195.25M | 203.11M |
| Total Equity | 0 | -6.07M | -6.77M |
| Cash & Equivalents | - | 1.36M | 1.43M |
| Total Liabilities | - | 7.75M | 8.32M |
| Current Liabilities | - | 727.32K | 1.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -422.08K |
| Investing Cash Flow | 500.00K |
| Financing Cash Flow | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | -107.7% |
| ROCE % | -0.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | AQR Arbitrage LLC | 6.69% | 1.32M | $14.26M |
| 2 | Fort Baker Capital Management LP | 5.59% | 1.11M | $11.91M |
| 3 | Decagon Asset Management LLP | 5.52% | 1.09M | $11.75M |
| 4 | Empyrean Capital Partners, LP | 4.55% | 900.00K | $9.69M |
| 5 | Shaw D.E. & Co., Inc. | 4.36% | 861.62K | $9.28M |
| 6 | Boussard & Gavaudan Investment Management LLP | 3.64% | 720.00K | $7.76M |
| 7 | Boussard & Gavaudan Gestion Sas | 3.64% | 720.00K | $7.76M |
| 8 | Linden Advisors LP | 3.03% | 600.00K | $6.46M |
| 9 | Toronto Dominion Bank | 2.80% | 554.29K | $5.97M |
| 10 | Sculptor Capital LP | 2.68% | 530.81K | $5.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OACC
Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Trading Up 0% - Still a Buy? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPVkFzT1ZFbnl2dXdOWVZ6UFdNZFpMOTZMTzMxSi1SRnk4QVQzekNrTjlUQklCVFpfNXNBMVFNYWRmZ0FQZmp4UFd2Sk9QUGxiYS11a0VnZ2szZWUwNUE5UXQ4MDdqUmE2VjBVWHA2R2hUUmZGUGdtRXhBVWI2eG1US1VjMzhjUTdmRUhnOF…
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (NASDAQ: OACC) Stock Price, News & Analysis - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE1DTS1YMU9WUkZ2UG1GUDBOWmtaWDUwMDBwdU5PQk9nd0ZCY08tQ3JVWlZlZmcxQmVQZUFpRDJ6MnNaTHJmcFd4Q2lPZS1nMGR3Zll2ZWtB?oc=5" target="_blank">Oaktree Acquisition Corp. III Life Sciences Class A…
Oaktree Acquisition Corp. III Life Sciences (OACC) Holds Steady Near Support in Quiet Trading - Volatility Breakout Picks - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxNZEcwNEtNUFo3MENjdEpnbXdTTDhCTHR5c043UkFFcFVmQXVkMEtVTUlzazR3LXBnYnBsTFdjd29pVjhVWkNjWDJ0aTNDX1lWZU5GMUNkaThCTC1xaUpmRU1uQ1pybXVBWnQzZW93aE1TMVpGb2VSRU0wd2ltS1NTZkxRM3ZSMmVld2l4an…
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (NASDAQ: OACC) Stock Price, News & Analysis - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1QOTlQTUYtZmU3a2cxUktuRzJTclAyZ3FsekpNNjU5UGNpODFmdEhQajBMZm5MdjNxWmJzdExzVHhqZlAxT2sxQ2V3bmlmLXBQ?oc=5" target="_blank">Oaktree Acquisition Corp. III Life Sciences Class A Ordinar…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBJdWpEdmQ0eHV4UlVEc2V4YkVoNVhlQlpfR1RYZ0k1Y1BxT1R4SHRubGtRZ2VBSS0za2QxR1I5RnlfUGJueFdHX2pZczRiRklP?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Oaktree Acquisition Corp. III Life Sciences (OACC) Holds Steady at $10.74 as SPAC Market Awaits Merger Catalyst - Advance Decline Volume - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPRGhpVW52R0Z2QjQ2SnJyUnlVdXVOdGZkXzNNSnNPQ0JuZXJsaEJfaEZkbFJUMDRJT2NNRDVzQmdZeEotTHJtVDREMWppdUNrQ0J2TjNXLTlZV1ZOR24yTUlFSklBMVJsbGx5Tkgycl8yMXl4d3lXVU9qN194UFNnUUh2cHVGcHJpMzV5YW…
OACC — Frequently Asked Questions
What is the current share price of Oaktree Acquisition Corp. III Life Sciences (OACC)?
As of 2026-09-19 21:16 PDT, Oaktree Acquisition Corp. III Life Sciences (OACC) trades at $10.80 on NasdaqGM. Its 52-week range is $10.30 to $10.80.
What is the market capitalisation of OACC?
Oaktree Acquisition Corp. III Life Sciences (OACC) has a market capitalisation of $213.66M on NasdaqGM.
What is the P/E ratio of OACC?
OACC trades at a trailing price-to-earnings (P/E) ratio of 38.57. The industry average P/E is 12.89. Its price-to-book (P/B) ratio is -35.32.
What is the return on equity (ROE) of OACC?
OACC has a return on equity (ROE) of -107.66%. Its return on capital employed (ROCE) is -0.59%.
Is OACC a good stock to buy?
This page provides a data-driven analysis of Oaktree Acquisition Corp. III Life Sciences (OACC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.